Leading neuro-drug development, rejuvenating cellular vitality
。 Multidisciplinary Expertise
A premier academic spin-off merging experts across biology, chemistry, and clinical medicine.
。 Translational Science
Accelerating the drug development lifecycle by integrating AI screening with preclinical and clinical translation.
。 Small Molecule Candidates
Dedicated to advancing safe, effective, and patient-friendly therapies for neurological disorders.
。 Global Collaboration
Driving global partnerships and licensing to accelerate clinical progress and create stakeholder value.
History and Milestones
2026
Startup Spin-off
2025
RN101 IND Approval
2024
ReNeu Preparatory Office Established
Company Organization
Management Team
-
Jerry Lin, Ph.D.
Chief Executive Officer & Co-founderBusiness Development -
KC Wu, Ph.D., R.Ph.
Chief Translational Officer & Co-founderResearch & Early Development -
Jean Wu, M.S., R.Ph.
Chief Administrative Officer & Co-founderProject Management & Clinical Affairs
Financial Advisor
-
-
Audrey Tseng
Honorary Deputy Chairman of PwC TaiwanFinancial Planning and Development Strategy -
Drug Development Advisor
-
-
Diane Tang-Liu, Ph.D.
DTL BioPharma, Inc
AiViva BioPharma, IncTranslational Drug Development -
Scientific Advisors
-
Chun-Jung Lin, Ph.D.
National Taiwan UniversityPharmacokinetics / Biopharmaceutics -
Jim-Min Fang, Ph.D.
Academia Sinica / National Taiwan University
Organic Synthesis / Chemical Biology -
Yun-Lian Lin, Ph.D.
China Medical UniversityNatural Products Chemistry
-
Jung-Hsing Lin, Ph.D.
Academia SinicaAI-based Drug Discovery -
Fang-Chia Chang, Ph.D.
National Taiwan University
Neuroscience -
If you're interested in our research, products, or collaboration opportunities, please complete the inquiry form. We will contact you as soon as possible. Your messages and feedback are invaluable to our continued progress!